RT Journal Article
SR Electronic
T1 Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4925
OP 4931
DO 10.21873/anticanres.13680
VO 39
IS 9
A1 ESA JARKKO MIKAEL KARI
A1 MILLA ELVI LINNEA KUUSISTO
A1 JAN BÖHM
A1 KIRSI-MARIA HAAPASAARI
A1 HANNA-RIIKKA TEPPO
A1 PEETER KARIHTALA
A1 ANNA HAKALAHTI
A1 TAINA TURPEENNIEMI-HUJANEN
A1 OUTI KUITTINEN
YR 2019
UL http://ar.iiarjournals.org/content/39/9/4925.abstract
AB Background/Aim: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy where antioxidant enzyme peroxiredoxin 6 (Prx6) has previously been associated with adverse outcomes. Its systemic effects in DLBCL are unknown. Materials and Methods: This study included 53 patients with DLBCL, five patients with primary central nervous system lymphoma (PCNSL) and 20 healthy controls. The expression of Prx6 was evaluated immunohistochemically in DLBCL tissue samples and compared to its expression in blood serum. Results: Prx6 expression was the highest in healthy controls, followed by DLBCL patients and PCNSL patients. Febrile neutropenic infection after the first treatment course was associated with low pre-treatment Prx6 serum levels (<14 ng/ml) (p=0.025, OR=8.615, 95% confidence interval=1.032-71.933). Serum levels of Prx6 recovered after treatment (p=0.006). Conclusion: Patients with low Prx6 levels might be more prone to treatment-related adverse effects through elevated levels of oxidative stress.